Early data hint at sub-blockbuster add-on for Alexion's billion dollar antibody
This article was originally published in Scrip
Alexion Pharmaceuticals has presented positive data from a Phase II single-arm study of its blockbuster Soliris (eculizumab) in a new potential indication, the prevention of antibody-mediated rejection (AMR), a severe and life-threatening complication in certain patients undergoing kidney transplantation. If the preliminary study findings are confirmed – they indicate that around 20% of kidney used in transplants might not be wasted through organ rejection - Alexion’s antibody could take a reasonable share in a $1.4bn market for kidney sparing in transplantation.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.